A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Condition:   Ovarian Cancer Interventions:   Drug: Olaparib;   Drug: Ceralasertib;   Drug: Placebo to match olaparib Sponsors:   AstraZeneca;   Parexel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials